Cite
HARVARD Citation
Chen, R. et al. (2015). Phase II study of pembrolizumab (MK-3475) for relapsed/refractory classical Hodgkin Lymphoma (r/r cHL): keynote-087. Journal for immunotherapy of cancer. 3 (2), pp. 1-2. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Chen, R. et al. (2015). Phase II study of pembrolizumab (MK-3475) for relapsed/refractory classical Hodgkin Lymphoma (r/r cHL): keynote-087. Journal for immunotherapy of cancer. 3 (2), pp. 1-2. [Online].